PF-Atlas › Clinical Trials › NCT04224272
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
ZW25 · Phase 2
Registry ID
NCT04224272
Phase
Phase 2
Status
Completed
Drug / intervention
ZW25 (Zanidatamab)
Sponsor
Jazz Pharmaceuticals
Start
2020-06-10
About this trial
ZW25 is evaluated in NCT04224272, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Jazz Pharmaceuticals. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04224272 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.